4 key lessons learnt from choosing in-house assay development

A key consideration in advanced therapy product characterization is choosing between an in-house developed assay solution or a commercial kit for quantitating residual DNA within a bioproduction workflow. The development and validation process for residual DNA analytical assays can be fraught with challenges. Here are four illustrative case studies to explain the real-life pitfalls that one may encounter when pursuing an in-house solution.



Please enter your email to access content Read now